Avapritinib in CBF-AML With KIT Mutations
NCT05821738
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Core Binding Factor Acute Myeloid Leukemia
KIT Mutation-Related Tumors
Interventions
DRUG:
Avapritinib
Sponsor
The First Affiliated Hospital of Soochow University